Raymond James & Associates Raises Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Raymond James & Associates boosted its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 6.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 87,049 shares of the company’s stock after acquiring an additional 5,377 shares during the quarter. Raymond James & Associates’ holdings in scPharmaceuticals were worth $546,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SCPH. Rice Hall James & Associates LLC lifted its position in shares of scPharmaceuticals by 9.1% during the third quarter. Rice Hall James & Associates LLC now owns 87,071 shares of the company’s stock worth $620,000 after purchasing an additional 7,241 shares during the last quarter. Tejara Capital Ltd bought a new stake in scPharmaceuticals during the 3rd quarter valued at about $722,000. Worth Venture Partners LLC boosted its position in scPharmaceuticals by 5.3% in the 3rd quarter. Worth Venture Partners LLC now owns 539,665 shares of the company’s stock valued at $3,842,000 after buying an additional 27,328 shares during the period. AIGH Capital Management LLC boosted its position in scPharmaceuticals by 7.6% in the 3rd quarter. AIGH Capital Management LLC now owns 2,207,009 shares of the company’s stock valued at $15,714,000 after buying an additional 155,204 shares during the period. Finally, Rubric Capital Management LP grew its stake in scPharmaceuticals by 234.3% in the 3rd quarter. Rubric Capital Management LP now owns 2,713,287 shares of the company’s stock worth $19,319,000 after acquiring an additional 1,901,770 shares in the last quarter. Institutional investors own 89.52% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, March 14th.

scPharmaceuticals Stock Performance

Shares of scPharmaceuticals stock opened at $4.35 on Friday. The company has a current ratio of 7.08, a quick ratio of 6.40 and a debt-to-equity ratio of 1.04. The stock’s fifty day moving average price is $5.29 and its 200-day moving average price is $5.53. The firm has a market cap of $156.82 million, a P/E ratio of -3.06 and a beta of 0.06. scPharmaceuticals Inc. has a 12 month low of $4.25 and a 12 month high of $12.75.

scPharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.07. scPharmaceuticals had a negative net margin of 403.22% and a negative return on equity of 97.18%. The company had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $6.10 million. On average, equities research analysts expect that scPharmaceuticals Inc. will post -1.47 earnings per share for the current fiscal year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.